|
|
||||||||
Ann Thorac Surg 2006;81:1736-1737
© 2006 The Society of Thoracic Surgeons
Bulfinch 119, Department of Surgery, Massachusetts General Hospital, Boston, MA 02114
(Email: olivier.dormand@tbrc.mgh.harvard.edu; madsen@helix.mgh.harvard.edu).
| The first 20% of the full text of this article appears below. |
The use of endothelial progenitor cells (EPCs) in the treatment of ischemic disease is a promising new approach. Multiple reports in animal models have shown that the injection of ex vivo expanded EPCs or stem cell progenitors can home sites of ischemia and participate to vasculogenesis [1]. Moreover, initial trials in human demonstrated that the use of ex vivo expanded progenitor cells is safe and improves blood supply to ischemic tissue. Injection of EPCs in patients with acute myocardial infarction improved left ventricular function and coronary flow
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |